Evidence map›Paper›PMID 28802838›Full record

ArticleJournal of biomedical informatics2017

Identification of immune correlates of protection in Shigella infection by application of machine learning.

Jorge M Arevalillo, Marcelo B Sztein, Karen L Kotloff, Myron M Levine, Jakub K Simon

Open access · greenAbstract read
In one paragraph

Article in Journal of biomedical informatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. mSphere · 2021
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Novel Strategies for Malaria Vaccine Design.Frontiers in immunology · 2018
    Review
  14. Transcriptomics in Human Challenge Models.Frontiers in immunology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Jorge M ArevalilloDepartment of Statistics and Operational Research, University Nacional Educación a Distancia, Paseo Senda del Rey 9, 28040 Madrid, Spain. Electronic address: jmartin@ccia.uned.es.
Marcelo B SzteinCenter for Vaccine Development, Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: msztein@medicine.umaryland.edu.
Karen L KotloffCenter for Vaccine Development, Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: KKOTLOFF@medicine.umaryland.edu.
Myron M LevineCenter for Vaccine Development, Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: MLevine@medicine.umaryland.edu.
Jakub K SimonMerck & Co., Inc., Kenilworth, NJ, USA. Electronic address: jakub.simon@merck.com.
University of Maryland, Baltimore · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USUniversidad Nacional de Educación a Distancia · ES

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WHITE, OWEN R · 2009 to 2018
$27.8M
Immunological Correlates of Protection in ShigellosisK23AI065759 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMON, JAKUB K · 2005 to 2009
$809k
NIAID NIH HHS K23 AI065759NIAID NIH HHS U19 AI082655
6 · The paper itself

Abstract

backgroundImmunologic correlates of protection are important in vaccine development because they give insight into mechanisms of protection, assist in the identification of promising vaccine candidates, and serve as endpoints in bridging clinical vaccine studies. Our goal is the development of a methodology to identify immunologic correlates of protection using the Shigella challenge as a model.

methodsThe proposed methodology utilizes the Random Forests (RF) machine learning algorithm as well as Classification and Regression Trees (CART) to detect immune markers that predict protection, identify interactions between variables, and define optimal cutoffs. Logistic regression modeling is applied to estimate the probability of protection and the confidence interval (CI) for such a probability is computed by bootstrapping the logistic regression models.

resultsThe results demonstrate that the combination of Classification and Regression Trees and Random Forests complements the standard logistic regression and uncovers subtle immune interactions. Specific levels of immunoglobulin IgG antibody in blood on the day of challenge predicted protection in 75% (95% CI 67-86). Of those subjects that did not have blood IgG at or above a defined threshold, 100% were protected if they had IgA antibody secreting cells above a defined threshold. Comparison with the results obtained by applying only logistic regression modeling with standard Akaike Information Criterion for model selection shows the usefulness of the proposed method.

conclusionGiven the complexity of the immune system, the use of machine learning methods may enhance traditional statistical approaches. When applied together, they offer a novel way to quantify important immune correlates of protection that may help the development of vaccines.

Indexed as

Machine LearningAlgorithmsDysentery, BacillaryHumansImmunoglobulin GLogistic ModelsModels, BiologicalImmunoglobulin GClassification and Regression TreesCorrelate of protectionLogistic regressionRandom Forests algorithmShigella

Identifiers

PMID28802838
PMCPMC5641263
OpenAlexW2744488601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.